ONCOTICS
Financiado
Probiotics for the Oncological Patients
The main objective of this project is to perform the technological/comercial and economical viability of the newly developped very gentle form of microbial lysis which preserves the biologically active molecules of probiotic bacte...
The main objective of this project is to perform the technological/comercial and economical viability of the newly developped very gentle form of microbial lysis which preserves the biologically active molecules of probiotic bacteria that favorably affects the cells of the intestinal mucosa and the mucosal immune system. This newly designed probioticsmodify the integrity of the intestinal mucosa damaged as a result of oncological treatment, to suppress inflammatory changes in the mucous membrane and, at the same time, to contribute to stabilization by the treatment of the disrupted microbiome. The ONCOTICS introduces novel treatment of intestines infections which brings : - Unique probiotical lysates product improving the oncology patients life comfort - New approach for elemination of syndrom leaky gut in oncological patients - Very safe gut barrier regeneration compared with standard probiotics, which can cuase sepsis - New patented technology for production of probiotics lysates - Novel therapy opening new markets
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2018-05-09
Fecha Fin: 2018-11-30
Fecha Fin: 2018-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
PHARMACEUTICAL BIOTECHNOLOGY SRO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
412.49K€ |
Participante